Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via deglycosylation of CD47
{{output}}
Background: Only a few bladder cancer patients benefit from anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy. The cluster of differentiation 47 (CD47) plays an important role in tumor immune evasi... ...
